The human pluripotent stem cell-lines used in this study were obtained with full Ethical/Institutional Review Board approval by the University of Edinburgh and validated using standard methods including chromosomal analysis, pluripotency and absence of plasmid integration. The iPSC lines CS02iCTR-NTn1 (hPSC1, male) and CS25iCTRL-18n2 (hPSC2, male) were obtained from Cedars-Sinai. For the Nfasc155-/- lines, fibroblasts were obtained by RS with ethical approval granted by the Institutional Review Board of Warsaw Medical University (Smigiel et al., 2018 (link)). The CS00iNK-n1 (Nfasc155-/-clone 1, female) and CS00iNK-n2 (Nfasc155-/-clone 2, female) iPSC lines were generated by Cedars-Sinai. The human embryonic stem cell-line SHEF4 (hPSC3, male) was obtained from the UK Stem Cell Bank. iPSCs were maintained on Matrigel (Scientific Laboratory Supplies)-coated 6-well plates in Essential 8 medium (Thermo Fisher Scientific) at 37 °C and 5% CO2. iPSC colonies were passaged by incubating in Dispase (0.5 mg/ml, Thermo Fisher Scientific)/Collagenase (1 mg/ml, Thermo Fisher Scientific) for 15-25 minutes at 37 °C, washed in DPBS and resuspended in Essential 8 medium before being redistributed in new 6-well plates. Cultures were regularly tested and maintained mycoplasma free. These cell-lines have not been authenticated.
Free full text: Click here